pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 23·1 min read
save

Merck CEO warns Congress that restricting US-China biotech deals could cost America its biotech leadership

Jul 23, 2026·read at Endpoints ↗RegulatoryNegative

Merck CEO Rob Davis told Congress and the Trump administration that limiting or cutting off US-China dealmaking would jeopardize US biotech leadership.

He emphasized that collaboration with Chinese partners has been crucial for developing and licensing molecules, and that restrictions could hinder innovation and market access.

Davis cautioned that such policy moves could cause the United States to fall behind globally in biotech, urging lawmakers to consider the long-term impact on the industry.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Merck CEO cautions Congress on imposing limits on Chinese dealmaking”

read at Endpoints ↗
96 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoUpdated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futilityEndpoints
  • 5h agoClaret says its latest fund will have larger focus on European life sciencesEndpoints
  • 2d agoCAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and moreEndpoints
  • 2d agoAbbVie-allied ADARx aims for IPO with 3 drugs in the clinicEndpoints
  • 2d agoThe race to make new Ebola vaccines faces a cash crunchEndpoints